Japan conditional early approval and time-limited approval
Japan can approve a medicine for a serious disease on early data when a confirmatory trial would be hard to run, on condition that evidence is gathered after launch; for cell and tissue products a 2014 law allows a time-limited approval that must be confirmed within seven years.
Overview
Japan, statute. The 2014 amendments to the Pharmaceuticals and Medical Devices Act (PMD Act) created a conditional and time-limited approval for regenerative medical products, valid for up to seven years, on the basis of probable benefit and confirmed safety. A separate conditional early approval system for drugs was piloted by the Ministry of Health, Labour and Welfare from 2017 and given statutory footing by the 2019 amendment to the PMD Act, effective in 2020, alongside the Sakigake designation. Primary text: the PMDA's English pages on the Act and its review programmes.
How it works: a drug for a serious disease where a confirmatory trial is difficult or would take too long, and where exploratory trials show a certain level of efficacy and safety, may be approved with conditions such as post-marketing studies, registries and use restricted to specified institutions; the approval is reconsidered when the required data arrive. For regenerative products the time-limited approval must be converted to full approval, or lapse, within the set period.
Why it matters for oncology and the arguments: the systems are Japan's counterparts to the FDA's accelerated approval and the EU's conditional authorisation, and several cancer cell therapies and rare-cancer drugs have used them. The regenerative product route drew international criticism when products were approved on small, uncontrolled studies, and a few later failed to confirm benefit; supporters answer that the time limit is a stronger discipline than the open-ended confirmatory obligations that plagued accelerated approvals in the United States before the 2022 reforms.
Similar pages
not linked directly; found by shared links- TermFederal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments
Shares Full (traditional, regular) approval, FDORA 2022 accelerated approval reforms, Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Accelerated approval and the tag law.
- TermFDASIA 2012 and the origins of the expedited programmes
Shares Fast Track and RMAT designations, FDORA 2022 accelerated approval reforms, Accelerated approval, Regulatory divergence between regions and the tag law.
- TermChina Drug Administration Law (2019) and expedited pathways
Shares Conditional marketing authorisation (EU), Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Accelerated approval, Regulatory divergence between regions and the tag law.
- TermRegulation (EC) No 726/2004: the EU centralised procedure
Shares Fast Track and RMAT designations, Conditional marketing authorisation (EU), Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.
- TermCancer Drugs Fund (England)
Shares Full (traditional, regular) approval, Conditional marketing authorisation (EU), Accelerated approval and the tag law.
- TermILAP (Innovative Licensing and Access Pathway)
Shares Fast Track and RMAT designations, Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.
- Term21st Century Cures Act
Shares Fast Track and RMAT designations, Accelerated approval and the tag law.
- TermMedicines and Medical Devices Act 2021
Shares Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.